[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Alzheimer's Disease - Pipeline Review, H1 2019

April 2019 | 1429 pages | ID: A987E347D4BEN
Global Markets Direct

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Alzheimer's Disease - Pipeline Review, H1 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 25, 56, 60, 5, 295, 109 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 97 and 43 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Alzheimer's Disease - Overview
Alzheimer's Disease - Therapeutics Development
Alzheimer's Disease - Therapeutics Assessment
Alzheimer's Disease - Companies Involved in Therapeutics Development
Alzheimer's Disease - Drug Profiles
Alzheimer's Disease - Dormant Projects
Alzheimer's Disease - Discontinued Products
Alzheimer's Disease - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Alzheimer's Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Alzheimer's Disease - Pipeline by 2A Pharma AB, H1 2019
Alzheimer's Disease - Pipeline by 4D Pharma Plc, H1 2019
Alzheimer's Disease - Pipeline by AB Science SA, H1 2019
Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2019
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2019
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2019
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2019
Alzheimer's Disease - Pipeline by Affichem SA, H1 2019
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2019
Alzheimer's Disease - Pipeline by Alector Inc, H1 2019
Alzheimer's Disease - Pipeline by AlfaSigma SpA, H1 2019
Alzheimer's Disease - Pipeline by Allergan Plc, H1 2019
Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by ALSP Inc, H1 2019
Alzheimer's Disease - Pipeline by AlzeCure Pharma AB, H1 2019
Alzheimer's Disease - Pipeline by Alzheon Inc, H1 2019
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2019
Alzheimer's Disease - Pipeline by Alzinova AB, H1 2019
Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2019
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2019
Alzheimer's Disease - Pipeline by Amgen Inc, H1 2019
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2019
Alzheimer's Disease - Pipeline by Aphios Corp, H1 2019
Alzheimer's Disease - Pipeline by Apodemus AB, H1 2019
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2019
Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2019
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2019
Alzheimer's Disease - Pipeline by Artery Therapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by Arvinas Inc, H1 2019
Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2019
Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2019
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2019
Alzheimer's Disease - Pipeline by Auritec Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Avanir Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2019
Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by Axxam SpA, H1 2019
Alzheimer's Disease - Pipeline by AZTherapies Inc, H1 2019
Alzheimer's Disease - Pipeline by BCWorld Pharm Co Ltd, H1 2019
Alzheimer's Disease - Pipeline by Beactica AB, H1 2019

LIST OF FIGURES

Number of Products under Development for Alzheimer's Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019

COMPANIES MENTIONED

2A Pharma AB
4D Pharma Plc
AB Science SA
AbbVie Inc
AC Immune SA
Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
Affichem SA
AFFiRiS AG
Alector Inc
AlfaSigma SpA
Allergan Plc
Allgenesis Biotherapeutics Inc
ALSP Inc
AlzeCure Pharma AB
Alzheon Inc
Alzhyme Pty Ltd
Alzinova AB
AlzProtect SAS
Amarantus Bioscience Holdings Inc
Amgen Inc
Anavex Life Sciences Corp
Aphios Corp
Apodemus AB
Applied Research using OMIC Sciences SL
Araclon Biotech SL
Archer Pharmaceuticals Inc
ArmaGen Inc
Artery Therapeutics Inc
Arvinas Inc
Asceneuron SA
Astellas Pharma Inc
AstraZeneca Plc
Auritec Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Avineuro Pharmaceuticals Inc
Axon Neuroscience SE
Axsome Therapeutics Inc
Axxam SpA
AZTherapies Inc
BCWorld Pharm Co Ltd
Beactica AB
Berg LLC
BioArctic AB
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioHealthonomics Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim GmbH
Bolder Biotechnology Inc
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Bsim2
Cantabio Pharmaceuticals Inc
Carna Biosciences Inc
Cassava Sciences Inc
Celon Pharma SA
Center Laboratories Inc
Cerecin Inc
CHA Bio & Diostech Co Ltd
Chong Kun Dang Pharmaceutical Corp
Clera Inc
CMG Pharmaceutical Co Ltd
Cognition Therapeutics Inc
Cognosci Inc
CohBar Inc
Corium International Inc
Cortice Biosciences Inc
Cotinga Pharmaceuticals Inc
Crossbeta Biosciences BV
CTD Holdings Inc
Cypralis Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DanPET AB
Daval International Ltd
Denali Therapeutics Inc
Diffusion Pharmaceuticals Inc
Dong Wha Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Endece LLC
Epigen Biosciences Inc
F. Hoffmann-La Roche Ltd
Fujifilm Toyama Chemical Co Ltd
Fulcrum Therapeutics Inc
GemVax & KAEL Co Ltd
Genentech Inc
Genervon Biopharmaceuticals LLC
GeneScience Pharmaceuticals Co Ltd
GlaxoSmithKline Plc
GliaCure Inc
Glialogix Inc
Golden Biotechnology Corp
Grifols SA
H. Lundbeck AS
Hana Pharm Co Ltd
Hemostemix Inc
HitGen LTD
HSRx Group
ICB International Inc
Icure Pharmaceutical Inc
ID Pharma Co Ltd
Immungenetics AG
Immunwork Inc
Impel NeuroPharma Inc
Inflazome Ltd
Inmune Bio Inc
Instituto Biomar SA
Insys Therapeutics Inc
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
K-Stemcell Co Ltd
Kadmon Corp LLC
Kalgene Pharmaceuticals Inc
Karuna Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lipopharma Therapeutics SL
Living Cell Technologies Ltd
Lupin Ltd
M3 Biotechnology Inc
ManRos Therapeutics
MedDay SA
Medesis Pharma SA
MedImmune LLC
MEDRx Co Ltd
MeiraGTx Holdings Plc
Merck & Co Inc
MetrioPharm AG
MGC Pharmaceuticals Ltd
Mission Therapeutics Ltd
ModGene Pharma LLC
Montisera Ltd
NAL Pharmaceuticals Ltd
Nanna Therapeutics Ltd
Nanomerics Ltd
NatureWise Biotech & Medicals Corp
NeoNeuro SAS
Neuralstem Inc
Neurim Pharmaceuticals Ltd
Neuro Bio Ltd
Neuro-Sys SAS
Neurodyn Life Sciences Inc
NeuroGeneration Inc
NeuroGenetic Pharmaceuticals Inc
NeuroNascent Inc
NeurOp Inc
Neuropore Therapies Inc
NeuroScientific Biopharmaceuticals Ltd
Neurotez Inc
New World Laboratories Inc
NoNO Inc
Novartis AG
Nymox Pharmaceutical Corp
Ono Pharmaceutical Co Ltd
Oryzon Genomics SA
Ovensa Inc
Oxstem Ltd
P2D Inc
Panorama Research Inc
Peptron Inc
Pharmasum Therapeutics AS
Pharnext SA
Phoenix Biotechnology Inc
Prevacus Inc
Priavoid GmbH
Probiodrug AG
Progenra Inc
ProMIS Neurosciences Inc
Proteome Sciences Plc
Prothena Corp Plc
QR Pharma Inc
Quimatryx SL
Regenera Pharma Ltd
reMYND NV
ReNetX Bio
Revalesio Corp
Rodin Therapeutics Inc
Rodos BioTarget GmbH
Sage Therapeutics Inc
Samjin Pharm Co Ltd
Samumed LLC
Sangamo Therapeutics Inc
Sanofi
SBI Pharmaceuticals Co Ltd
Sentinel Oncology Ltd
Serometrix LLC
Shionogi & Co Ltd
Simcere Pharmaceutical Group
Sosei Heptares
Spherium Biomed SL
Summit Therapeutics Plc
Suven Life Sciences Ltd
T3D Therapeutics Inc
Takeda Pharmaceutical Co Ltd
TechnoPhage SA
Teikoku Pharma USA Inc
Telocyte LLC
Tetra Discovery Partners LLC
Teva Pharmaceutical Industries Ltd
Tonix Pharmaceuticals Holding Corp
Treventis Corp
UCB SA
United Neuroscience Ltd
Varinel Inc
Virobay Inc
Voyager Therapeutics Inc
vTv Therapeutics Inc
Vybion Inc
Xigen SA
Zensun (Shanghai) Sci & Tech Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
ZZ Biotech LLC


More Publications